Help Fund our new campaign with DCA and SAVE LIVES!

Dear patients, patrons and friends,

The Foundation for Collaborative Medicine and Research, (CollMED, www.collmed.org) is launching a campaign to fund our grant for a new test system to show which patients will respond to DCA even after all conventional chemo has failed. We have narrowed down the search and found two promising enzymes that are measured in the blood of patients and if elevated will show those patients who are responders. These lives we can still save with this new form of cancer therapy. Please help us to save lives TODAY! Give generously and help meet the goal so we can start immediately on this test. So many patients could have been saved and now we know which ones we can indeed save. You can be a part of this rewarding and exciting new research. Give today, please help make a difference in this world of suffering to a world of healing.

Brief description of the program/project-Cancer Research: FCMR has been successfully testing a new compound for cancer, Dichloroacetate (DCA). This compound has been in use since 1988 for the treatment of congenital lactic acidosis in children. However, recent findings indicated it may be successful in cancer patients. Through our research with patients, we have seen DCA successfully reverse Non Hodgkins lymphoma and Stage IV Medullary Thyroid cancer, normally a terminal state for this type of cancer. We suspect that we may have found a blood parameter to indicate whether or not a patient will respond to this type of therapy from DCA or other compounds with similar mechanisms. We wish to pursue laboratory diagnostics for a reliable indicator for future therapies with DCA and similar compounds in cancer patients. We expect to find this enzyme elevated in patients who would respond to DCA. If all conventional therapies have failed, they will be tested with DCA. Those patients who have an elevated enzyme should show a positive response by a reversal of tumors and a state of remission after a period of 6 months. This laboratory test can then be used for all cancer patients to show the pathophysiological state of the cancer, e.g. anaerobic metabolism, and the indication for new, additional therapies where other therapies have failed. We wish to test in other cancer dependent enzyme tests we are looking at for potential confirmation for efficacy of this compound.

FCMR has been very successful in similar studies finding other compounds that work in Pancreas cancer therapy and are being conducted in pilot studies to determine the efficacy of a new compound that is reversing the anaerobic metabolism in cancers. We have seen excellent results and remissions in Non Hodgkin’s Lymphoma, Medullary Thyroid Cancers and breast cancer patients with brain metastases. We are also testing new combination therapies and nutrient support for prostate cancer and pancreas patients internationally. Gastrointestinal tumors appeared responsive to these therapies. New work is being planned for lung cancer patients to coincide with one of the exciting new antibodies that activate the Immune system to fight the tumors. This latter antibody has shown itself successful in melanoma and is presently being investigated at multiple Universities for Kidney cancer and lung cancer.

History of organization/involvement with issues- The Foundation for Collaborative Medicine and Research, founded in 2001, has been involved in research in cancer with many new discoveries that enhance efficacies of conventional therapies, as well as developing new therapies for cancer that are resistant to standard conventional therapies. Dr. Flavin has been researching relevant literature, of (over one-half million articles since 1979), to find the most important aspects of nutrition and nutrient supplements for decreasing cancer risks and helping in therapy. In addition, our foundation is researching new therapies and methods for decreasing the symptoms in autoimmune diseases and viral diseases. Dr. Dana F. Flavin is in sharing her 27 years of research and expertise in Cancer and Cancer Prevention with scientists around the world and the public by giving presentations to interested associations and groups. Her expertise includes disciplines in medicine, chemistry, biochemistry, Nutrient biochemistry (summa cum laude) and Medicine with a specialty in Biochemical Pharmacology and Internal Medicine. She was the Science Assistant to the Associate Bureau Director for Toxicology, appointed from 1979-1981. She has been living and doing research in Germany and Austria for the past twenty years and was established in Greenwich CT , since September 2008 to run the foundation and share this valuable knowledge with the American general public in this country. Dr. Flavin is an advisor to her colleagues at the National Cancer Institutes in Germany , Austria , Italy ( Naples ) and the United States , as well as a resource for information to colleagues internationally.

Activities, Outline, Objectives & Goals-To raise funding for continued DCA research and therapies at the following labs:

Blood sample Research -

Dr. Schandl, MD

American Medical lab

1818 Sheridan Street, Suite 102

Hollywood, FL 33020

Tumor testing-

Dr. Sherry Bradford

Baird Research Park
1576 Sweet Home Road
Amherst , NY 14228

Starting Date-Ongoing research and development for 2010-2011

Funding Request-Total amount of funding needed for 2010 is $90,000. FCMR is requesting $50,000 this funding continue research and to secure lab testing. Because FCMR is a non-Profit Organization relying on donations from the public with no affiliation to any companies or profit organizations we urgently need public & private assistance.

Contact Info:

Dana Flavin, M.D., PhD
Foundation for Collaborative Medicine and Research
181 Clapboard Ridge Road Greenwich, CT 06831
Tel. 203.661.0911 | Cell 203.964.7011 | Fax
dana@collmed.com | www.collmed.org

Genevieve (Gena) Dillon
805.272.8023